동물용 구충제 세계 시장 : 유형별, 동물 유형별, 최종사용자별, 지역별 - 예측(-2031년)

The animal parasiticides market is expected to grow from USD 12.98 billion in 2026 to USD 17.50 billion by 2031, at a CAGR of 6.2%. This growth is driven by several key factors shaping the future of parasite prevention, including long-acting treatment solutions and precision-driven parasite management in veterinary care.

One of the most significant driving forces in the animal parasiticides market is the growing demand for more effective, targeted, and preventive parasite control strategies as veterinary healthcare professionals work to improve the accuracy, speed, and longevity of parasite control. As the trend in the companion animal healthcare industry continues to evolve to a data-driven and risk-based approach to parasite control, there is an increasing demand for high-quality parasiticides that can support precision dosing, resistance, and year-round protection. This has been further fueled by the use of analytics and digital health platforms, thus creating a demand for innovative and safe parasiticide products.

Pet owners face urgent demand for fast-acting, effective, and long-lasting solutions because parasite infestations, vector-borne diseases, and age-related pet vulnerability keep increasing in frequency. Veterinarians use advanced oral, topical, and injectable products to treat more patients while achieving better treatment results through reduced need for patient follow-ups. The rising parasite resistance problem and environmental parasite contamination issue compel scientists to develop new active ingredients and combination parasiticides for their research.

Formulation science and delivery system advancements, such as extended-release injectables, long-acting oral chewables, and enhanced topical formulations, are driving the market as they enhance efficacy, ease of use, and compliance. Such advancements enable effective preventive treatment, close treatment gaps, and improve real-world outcomes, thus accelerating the ongoing development and adoption of innovative solutions in the animal parasiticides market.

"By animal type, the companion animals segment is projected to exhibit a higher CAGR than the livestock segment during the forecast period."

The companion animals segment is expected to experience a high growth rate in the animal parasiticides market because of the rising number of pet owners, the increasing humanization of pets, and increased expenditures on preventive veterinary care. The growing awareness of parasite-borne diseases, combined with the strong adoption of year-round flea, tick, and heartworm prevention and innovative long-acting parasiticide products, has also fueled demand in this segment.

"By end user, the veterinary hospitals & clinics segment accounted for the largest market share in 2025."

In 2025, the veterinary hospitals & clinics segment dominated the animal parasiticides market because these facilities served as the main center for parasite control treatment delivery through their diagnostic and prescription capabilities. Pet owners and livestock producers depend on veterinarians to deliver expert product advice and preventive care solutions, which leads to increased sales of parasiticides at veterinary clinics. The combination of prescription-only products and advanced long-acting products, together with rising demand for routine check-ups and preventive care, has established veterinary hospitals and clinics as the primary distribution and treatment channel in the market.

"Latin America is expected to witness the highest growth rate during the forecast period."

Latin America is projected to be the fastest-growing regional market for animal parasiticides during the forecast period. The region's high market growth can be attributed to the expansion of livestock production, the increase in companion animal ownership, and a growing awareness of parasite prevention and animal health. Year-round favorable parasite living conditions due to the region's climate, enhanced availability of veterinary services, and increased use of modern parasiticide products are all factors that are speeding up the market growth in the Latin American region.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
• By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
• By Region: North America (45%), Europe (15%), Asia Pacific (25%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By End User: Veterinary Hospitals & Clinics (50%), Animal Farms (33%), and Home Care Settings (17%)

By Designation: Veterinarian/Chief Veterinary Officer (47%), Procurement/Purchasing Manager (22%), Head of Animal Health / Farm Manager (15%), and Others (16%)

• By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the animal parasiticides market in various segments. It aims to estimate the size and growth potential of this market by type, animal type, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

• Analysis of key drivers (rising pet ownership and increased focus on preventive animal healthcare and growing prevalence of ecto- and endoparasites), restraints (strict regulations on parasiticide residues in food-producing animals and high cost of premium and combination parasiticide products), opportunities (development of long-acting, combination, and novel-delivery parasiticides and expansion of parasiticide adoption in emerging markets), and challenges (increasing parasite resistance to existing active ingredients and stringent regulatory approval processes and varying regional compliance requirements) influencing the growth of the animal parasiticides market.
• Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the animal parasiticides market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of animal parasiticide products across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the animal parasiticides market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the animal parasiticides market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN ANIMAL PARASITICIDES MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ANIMAL PARASITICIDES MARKET OVERVIEW
• 3.2 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY TYPE AND COUNTRY (2025)
• 3.3 ANIMAL PARASITICIDES MARKET: REGIONAL GROWTH OPPORTUNITIES
• 3.4 ANIMAL PARASITICIDES MARKET: REGION (2026-2031)
• 3.5 ANIMAL PARASITICIDES MARKET: DEVELOPED VS. DEVELOPING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing zoonotic & vector-borne disease burden, creating mandatory treatment
    • 4.2.1.2 Expanding companion animal population and pet ownership
    • 4.2.1.3 Increasing demand for animal-derived food products
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Growing resistance to parasiticides
    • 4.2.2.2 Stringent regulatory approval processes for veterinary drugs
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 High growth potential of emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Uneven regulatory approval timelines across key markets, creating access inequalities
    • 4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCE ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 GDP, CURRENT PRICES (BILLIONS OF U.S. DOLLARS)
  • 5.2.4 GDP: CURRENT PRICES (USD BILLION)
  • 5.2.5 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
  • 5.2.6 TRENDS IN GLOBAL ANIMAL PARASITICIDES INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF ANIMAL PARASITICIDES, BY KEY PLAYER, 2023-2025
    • 5.5.1.1 Average selling price trend of ectoparasiticides, by key player, 2023-2025
    • 5.5.1.2 Average selling price trend of endoparasiticides, by key player, 2023-2025
    • 5.5.1.3 Average selling price trend of endectocides, by key player, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND OF ANIMAL PARASITICIDES, BY REGION, 2023-2025
    • 5.5.2.1 Average selling price trend of pour-on ectoparasiticides (USD per standard treatment unit), by region, 2023-2025
    • 5.5.2.2 Average selling price trend of spray ectoparasiticides (USD per standard treatment unit), by region, 2023-2025
    • 5.5.2.3 Average selling price trend of tablet ectoparasiticides (USD per standard treatment unit), by region, 2023-2025
    • 5.5.2.4 Average selling price trend of endoparasiticide oral solids (USD per standard treatment unit), by region, 2023-2025
    • 5.5.2.5 Average selling price trend of injectable endectocides (USD per standard treatment unit), by region, 2023-2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT DATA FOR HS CODE 30, 2021-2025
  • 5.6.2 IMPORT SCENARIO (HS CODE 30)
  • 5.6.3 EXPORT DATA FOR HS CODE 30, 2021-2025
  • 5.6.4 EXPORT SCENARIO (HS CODE 30)
• 5.7 KEY CONFERENCES AND EVENTS IN 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 CASE STUDY 1: BROAD-SPECTRUM COMBINATION ECTOPARASITICIDE + ENDOPARASITICIDE (ZOETIS - SIMPARICA TRIO)
  • 5.10.2 CASE STUDY 2: FIRST BROAD-SPECTRUM FELINE TOPICAL ENDECTOCIDE (BOEHRINGER INGELHEIM - NEXGARD COMBO)
  • 5.10.3 CASE STUDY 3: BROADEST-SPECTRUM CANINE ORAL PARASITICIDE WITH FOUR ACTIVE INGREDIENTS (ELANCO - CREDELIO QUATTRO)
• 5.11 ANIMAL PARASITICIDES MARKET: IMPACT OF 2025 US TARIFF
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
  • 5.11.5 IMPACT ON END USERS
    • 5.11.5.1 Veterinary hospitals & clinics
    • 5.11.5.2 Home care settings
    • 5.11.5.3 Animal farms

6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Long-acting/Extended-release parasiticides
    • 6.1.1.2 Novel multi-parasite combination therapies
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Immunomodulators for host-assisted parasitic control
    • 6.1.2.2 Nanobiosensors and rapid diagnostics for parasitic detection
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Entomopathogenic Fungi (EPF) for ticks and ectoparasites
    • 6.1.3.2 Precision livestock farming sensors and wearables
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 PUBLICATION TRENDS FOR ANIMAL PARASITICIDES
    • 6.3.1.1 Insights on patent publication trends, top applicants and jurisdiction for animal parasiticides, january 2015-may 2026
  • 6.3.2 LIST OF MAJOR PATENTS, 2023-2026
• 6.4 FUTURE APPLICATIONS
  • 6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT
  • 6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT
  • 6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK
  • 6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL
• 6.5 IMPACT OF AI/GENERATIVE AI ON ANIMAL PARASITICIDES MARKET
  • 6.5.1 INTRODUCTION
  • 6.5.2 MARKET POTENTIAL IN ANIMAL PARASITICIDES ECOSYSTEM
  • 6.5.3 AI USE CASES
  • 6.5.4 KEY COMPANIES IMPLEMENTING AI IN ANIMAL PARASITICIDES MARKET

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 7.1 DECISION-MAKING PROCESS
• 7.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.2.2 BUYING CRITERIA
• 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 7.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS
  • 7.4.1 VETERINARY HOSPITALS & CLINICS
  • 7.4.2 LIVESTOCK FARMS
  • 7.4.3 HOME CARE SETTINGS
• 7.5 MARKET PROFITABILITY
  • 7.5.1 PRODUCT INNOVATION AND DIFFERENTIATION
  • 7.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING
  • 7.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY

8 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 8.1 REGULATORY LANDSCAPE
  • 8.1.1 REGULATORY FRAMEWORK
    • 8.1.1.1 North America
    • 8.1.1.2 Europe
  • 8.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 8.1.3 INDUSTRY STANDARDS
    • 8.1.3.1 VICH Guidelines (International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products)
    • 8.1.3.2 Good Manufacturing Practice (GMP) Standards - PIC/S Guide (PE 009 series)
    • 8.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 - Maximum Residue Limits)
• 8.2 SUSTAINABILITY INITIATIVES
  • 8.2.1 ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN ANIMAL PARASITICIDES MARKET
  • 8.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
  • 8.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

9 ANIMAL PARASITICIDES MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 ECTOPARASITICIDES
  • 9.2.1 POUR-ONS & SPOT-ONS
    • 9.2.1.1 Ease of application and broad spectrum activity to drive continued adoption
    • 9.2.1.2 Global volume analysis of pour-ons & spot-ons, 2024-2031 (Thousand Units)
  • 9.2.2 ORAL TABLETS
    • 9.2.2.1 High medication compliance and ease of administration to drive market
    • 9.2.2.2 Global Volume Analysis of oral tablets, 2024-2031 (Thousand Units)
  • 9.2.3 SPRAYS
    • 9.2.3.1 Low price and convenience to drive market in emerging economies and livestock sector
    • 9.2.3.2 Global Volume Analysis of sprays, 2024-2031 (Thousand Units)
  • 9.2.4 DIPS
    • 9.2.4.1 High popularity ensures sustained end-user demand
    • 9.2.4.2 Global Volume Analysis of DIPS, 2024-2031 (Thousand Units)
  • 9.2.5 EAR TAGS
    • 9.2.5.1 High effectiveness in controlling flies around cattle drives market
    • 9.2.5.2 Global Volume Analysis of ear tags, 2024-2031 (Thousand Units)
  • 9.2.6 COLLARS
    • 9.2.6.1 Growing prevalence of infections in companion animals to drive adoption
    • 9.2.6.2 Global Volume Analysis of collars market, 2024-2031 (Thousand Units)
  • 9.2.7 OTHER ECTOPARASITICIDES
• 9.3 ENDOPARASITICIDES
  • 9.3.1 ORAL LIQUIDS
    • 9.3.1.1 Broad-spectrum activity to drive adoption across young animals and intensive livestock systems
    • 9.3.1.2 Global volume analysis of oral liquids, 2024-2031 (Thousand Units)
  • 9.3.2 ORAL SOLIDS
    • 9.3.2.1 Emergence of internal parasitic infections in dogs to drive market
    • 9.3.2.2 Global volume analysis of oral solids, 2024-2031 (Thousand Units)
  • 9.3.3 INJECTABLES
    • 9.3.3.1 Global volume analysis of injectables, 2024-2031 (Thousand Units)
    • 9.3.3.2 Standard/Short-acting injectables
      • 9.3.3.2.1 Veterinary preference for fast-acting injectable formulations in acute parasitic infections drives market growth
    • 9.3.3.3 Long-acting/Extended-release injectables
      • 9.3.3.3.1 Emergence of internal parasitic infections in dogs to drive market
  • 9.3.4 FEED ADDITIVES
    • 9.3.4.1 Can be administered to large number of animals at once
    • 9.3.4.2 Global volume analysis of feed additives, 2024-2031 (Thousand Units)
  • 9.3.5 OTHER ENDOPARASITICIDES
• 9.4 ENDECTOCIDES
  • 9.4.1 ORAL ENDECTOCIDES
    • 9.4.1.1 Growing pet owner preference for systemic all-in-one protection to accelerate oral endectocide demand
    • 9.4.1.2 Global volume analysis of oral endectocides, 2024-2031 (Thousand Units)
  • 9.4.2 INJECTABLE ENDECTOCIDES
    • 9.4.2.1 Single-injection dual-action convenience underpins dominance in cattle and swine production systems
    • 9.4.2.2 Global volume analysis of injectable endectocides, 2024-2031 (Thousand Units)
  • 9.4.3 TOPICAL ENDECTOCIDES
    • 9.4.3.1 Convenience, zero-injection compliance, and expanding multi-spectrum topical formulations sustain demand
    • 9.4.3.2 Global volume analysis of topical endectocides, 2024-2031 (Thousand Units)

10 ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE

• 10.1 INTRODUCTION
• 10.2 COMPANION ANIMALS
  • 10.2.1 DOGS
    • 10.2.1.1 Increasing adoption of dogs to drive market growth
  • 10.2.2 CATS
    • 10.2.2.1 Rising feline parasiticide adoption, low preventive compliance, and broad-spectrum product launches drive growth
  • 10.2.3 HORSES
    • 10.2.3.1 Higher risk of traumatic injuries in horses to drive demand
  • 10.2.4 OTHER COMPANION ANIMALS
• 10.3 LIVESTOCK ANIMALS
  • 10.3.1 CATTLE
    • 10.3.1.1 Gastrointestinal nematodes and tick-borne disease drive systemic endectocide and acaricide demand
  • 10.3.2 PIG
    • 10.3.2.1 Growing surgical volume for acute conditions in swine to drive market growth
  • 10.3.3 POULTRY
    • 10.3.3.1 Growing focus on infection prevention and flock health management propels growth
  • 10.3.4 SHEEP & GOAT
    • 10.3.4.1 Growth in consumption of sheep and goat meat to drive market
  • 10.3.5 OTHER LIVESTOCK ANIMALS

11 ANIMAL PARASITICIDES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 VETERINARY HOSPITALS & CLINICS
  • 11.2.1 VETERINARY HOSPITALS & CLINICS TO DOMINATE MARKET DURING FORECAST PERIOD
• 11.3 ANIMAL FARMS
  • 11.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM PARASITE MANAGEMENT
• 11.4 HOME CARE SETTINGS
  • 11.4.1 RISING PET EXPENDITURE TO PROPEL MARKET GROWTH

12 ANIMAL PARASITICIDES MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 NORTH AMERICA: ANIMAL PARASITICIDES MARKET VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 12.2.3 US
    • 12.2.3.1 Surge in animal healthcare expenditure to boost market growth
  • 12.2.4 CANADA
    • 12.2.4.1 Growing pet ownership and increasing focus on preventive animal healthcare to drive market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 EUROPE: ANIMAL PARASITICIDES MARKET VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 12.3.3 GERMANY
    • 12.3.3.1 Strong focus on animal welfare and advanced veterinary care to drive market growth
  • 12.3.4 UK
    • 12.3.4.1 Increasing pet ownership and rising animal healthcare spending to propel market growth
  • 12.3.5 FRANCE
    • 12.3.5.1 High standards of veterinary care and technological advancements to support market growth
  • 12.3.6 ITALY
    • 12.3.6.1 Growing pet ownership awareness and increasing livestock population to drive market growth
  • 12.3.7 SPAIN
    • 12.3.7.1 Increasing awareness regarding animal health to drive market growth
  • 12.3.8 NETHERLANDS
    • 12.3.8.1 Growing pet ownership and strong livestock sector to support market growth
  • 12.3.9 SWEDEN
    • 12.3.9.1 Growing companion animal care and advanced veterinary infrastructure supporting market growth
  • 12.3.10 POLAND
    • 12.3.10.1 Rapid expansion of poultry production and export-oriented farming increases demand
  • 12.3.11 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 12.4.3 CHINA
    • 12.4.3.1 China to register highest growth rate during forecast period
  • 12.4.4 JAPAN
    • 12.4.4.1 Rising pet care expenditure and increasing adoption of companion animals to drive market growth
  • 12.4.5 INDIA
    • 12.4.5.1 Increasing livestock population to propel market growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
  • 12.4.7 SOUTH KOREA
    • 12.4.7.1 Growing pet ownership to favor growth
  • 12.4.8 THAILAND
    • 12.4.8.1 Growing focus on livestock health and disease prevention to drive market growth
  • 12.4.9 NEW ZEALAND
    • 12.4.9.1 Growing pet ownership and focus on preventive animal healthcare to support market growth
  • 12.4.10 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 LATIN AMERICA: ANIMAL PARASITICIDES MARKET VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 12.5.3 BRAZIL
    • 12.5.3.1 Brazil to dominate Latin American market
  • 12.5.4 MEXICO
    • 12.5.4.1 Robust livestock base and growing companion animal care drive market
  • 12.5.5 ARGENTINA
    • 12.5.5.1 Expanding livestock production and increasing focus on disease prevention to drive market growth
  • 12.5.6 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 MIDDLE EAST & AFRICA: ANIMAL PARASITICIDES MARKET VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
• 12.7 GCC COUNTRIES
  • 12.7.1 KINGDOM OF SAUDI ARABIA (KSA)
    • 12.7.1.1 Market growth driven by Vision 2030 investments
  • 12.7.2 UNITED ARAB EMIRATES (UAE)
    • 12.7.2.1 Increasing focus on livestock health and companion animal care to support market growth
  • 12.7.3 OTHER GCC COUNTRIES
  • 12.7.4 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
  • 13.1.1 KEY STRATEGIES ADOPTED BY PLAYERS IN ANIMAL PARASITICIDES MARKET
• 13.2 REVENUE ANALYSIS, 2023-2025
• 13.3 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 13.3.1 US ANIMAL PARASITICIDES MARKET SHARE ANALYSIS, 2025
  • 13.3.2 EUROPE ANIMAL PARASITICIDES MARKET SHARE ANALYSIS, 2025
• 13.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.4.1 STARS
  • 13.4.2 EMERGING LEADERS
  • 13.4.3 PERVASIVE PLAYERS
  • 13.4.4 PARTICIPANTS
  • 13.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 13.4.5.1 Company footprint
    • 13.4.5.2 Region footprint
    • 13.4.5.3 Product type footprint
    • 13.4.5.4 Animal type footprint
• 13.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 13.5.1 PROGRESSIVE COMPANIES
  • 13.5.2 RESPONSIVE COMPANIES
  • 13.5.3 DYNAMIC COMPANIES
  • 13.5.4 STARTING BLOCKS
  • 13.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 13.5.5.1 List of startups/SMEs
    • 13.5.5.2 Competitive benchmarking of startups/SMEs
• 13.6 COMPANY VALUATION AND FINANCIAL METRICS
• 13.7 PRODUCT/BRAND COMPARISON
• 13.8 COMPETITIVE SITUATIONS & TRENDS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ZOETIS INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches & approvals
      • 14.1.1.3.2 Expansions
      • 14.1.1.3.3 Other developments
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 MERCK & CO., INC
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches & approvals
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches & approvals
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 ELANCO
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches & approvals
      • 14.1.4.3.2 Expansions
      • 14.1.4.3.3 Other developments
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 VIRBAC
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches & approvals
      • 14.1.5.3.2 Deal
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 CEVA
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
      • 14.1.6.3.2 Expansions
  • 14.1.7 VETOQUINOL
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 NORBROOK
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches & approvals
      • 14.1.8.3.2 Expansions
  • 14.1.9 BIMEDA CORPORATE
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches & approvals
      • 14.1.9.3.2 Deals
      • 14.1.9.3.3 Expansions
  • 14.1.10 KYORITSU SEIYAKU CORPORATION
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
  • 14.1.11 KRKA, D. D., NOVO MESTO
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 ECO - ANIMAL HEALTH LTD.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 ALIVIRA ANIMAL HEALTH LIMITED
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
      • 14.1.13.2.1 Recent developments
      • 14.1.13.2.2 Deals
  • 14.1.14 OUROFINO SAUDE ANIMAL
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
  • 14.1.15 HEBEI VEYONG PHARMACEUTICAL CO., LTD.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 CHANELLE PHARMA
  • 14.2.2 PETIQ LLC
  • 14.2.3 HUVEPHARMA
  • 14.2.4 CALIER
  • 14.2.5 ABBEY LABS
  • 14.2.6 BIOGENESIS BAGO
  • 14.2.7 VETANCO SA
  • 14.2.8 HESTER BIOSCIENCES LIMITED
  • 14.2.9 BRILLIANT BIO PHARMA
  • 14.2.10 ASHISH LIFE SCIENCE

15 RESEARCH METHODOLOGY

• 15.1 RESEARCH APPROACH
• 15.2 RESEARCH METHODOLOGY DESIGN
  • 15.2.1 SECONDARY RESEARCH
    • 15.2.1.1 Key data from secondary sources
  • 15.2.2 PRIMARY DATA
    • 15.2.2.1 Key data from primary sources
    • 15.2.2.2 Key industry insights
• 15.3 MARKET SIZE ESTIMATION
  • 15.3.1 APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 15.3.2 APPROACH 2: COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 15.3.3 APPROACH 3: DEMAND-SIDE ANALYSIS
  • 15.3.4 APPROACH 4: TOP-DOWN APPROACH
  • 15.3.5 APPROACH 5: BOTTOM-UP APPROACH
• 15.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 15.5 MARKET SHARE ESTIMATION
• 15.6 RESEARCH ASSUMPTIONS
• 15.7 RISK ASSESSMENT
• 15.8 RESEARCH LIMITATIONS
  • 15.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 15.8.2 SCOPE-RELATED LIMITATIONS

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
  • 16.3.1 PRODUCT ANALYSIS
  • 16.3.2 COMPANY INFORMATION
  • 16.3.3 GEOGRAPHIC ANALYSIS
  • 16.3.4 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
  • 16.3.5 BY TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
  • 16.3.6 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS